MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next

Author: Jelena Martinovic | September 20, 2023 09:42am

MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) has executed a supplementary agreement to its asset purchase agreement with 1193269 B.C. Ltd., operating as Shelter Cannabis for the Shelter Cannabis Brands IP portfolio, ending any ongoing royalty payments after August 31, 2023.

Under the existing asset purchase agreement, executed in March 2022, MediPharm Labs purchased the IP of Shelter Cannabis Brands. This IP has been focused in the market on Wildlife Cannabis domestic dry flower and pre-roll products that are manufactured and distributed via the MediPharm sites.

Why It Matters

The supplementary agreement allows for an improvement in this product line's gross margin, providing flexibility for the Toronto-based company to further invest in the brand to drive sales as it continues on the path to profitability.

What's Next

MediPharm said on Wednesday that it will continue to review every product category and selling channel to optimize margins and streamline business operations to achieve its profitability goal.

MediPharm's Research Efforts

Meanwhile, MediPharm is no stranger to innovation either.

Its Harvest Medicine subsidiary recently conducted a study that revealed that medical cannabis may effectively manage fibromyalgia and associated symptoms of depression and anxiety.

The research showed that 75% of patients who mainly used CBD oil saw a decrease in their self-reported illness severity, which may include chronic pain, insomnia, and fatigue.

To learn more about cannabis innovation, come join us at the upcoming Benzinga marijuana event in Chicago.

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.